Table 2.
Clinical, demographic and laboratory parameters of the 303 APS patients grouped according to the positivity for B2-CIC.
| CONDITION | B2-CIC positive N=119, 39.3% | B2-CIC negative N=184, 60.7% | p-value | OR/Hodges-Lehmann median difference (95% CI) | ||
|---|---|---|---|---|---|---|
| N/median | %/IQR | N/median | %/IQR | |||
| Age (years) | 46.0 | 36.3-56.8 | 48.0 | 39.0-57.0 | 0.533 | |
| Sex (women) | 92 | 77.3 | 128 | 69.6 | 0.141 | |
| Disease duration (years) | 5.0 | 2.0-9.0 | 6.0 | 2.0-11.0 | 0.259 | |
| Systemic lupus erythematosus | 42 | 35.3 | 70 | 38.0 | 0.628 | |
| Diabetes mellitus | 7 | 9.1 | 15 | 13.0 | 0.458 | |
| Arterial hypertension | 23 | 19.3 | 39 | 21.2 | 0.694 | |
| Dyslipidemia | 24 | 20.2 | 34 | 18.5 | 0.716 | |
| Active smoker | 9 | 7.6 | 23 | 12.5 | 0.173 | |
| Primary APS | 64 | 53.8 | 101 | 54.9 | 0.850 | |
| SAD-APS | 55 | 46.2 | 83 | 45.1 | 0.850 | |
| Catastrophic APS | 1 | 0.8 | 7 | 3.8 | 0.154 | |
| Isolated gestational morbidity | 35 | 29.4 | 32 | 17.4 | 0.014 | 1.98 (1.14-3.43) |
| Isolated thrombotic APS | 73 | 61.3 | 123 | 66.8 | 0.329 | |
| Inf. extr. deep vein thrombosis | 35 | 29.4 | 58 | 31.5 | 0.521 | |
| Superficial thrombophlebitis | 19 | 16.0 | 23 | 12.5 | 0.394 | |
| Sup. extr. arterial thrombosis | 1 | 0.8 | 8 | 4.3 | 0.083 | |
| Acute myocardial infarction | 6 | 5.0 | 8 | 4.3 | 0.779 | |
| Stroke | 22 | 18.5 | 42 | 22.8 | 0.366 | |
| Pulmonary embolism | 8 | 6.7 | 21 | 11.4 | 0.176 | |
| Chorea | 3 | 2.5 | 3 | 1.6 | 0.683 | |
| Epilepsy | 4 | 3.4 | 14 | 7.6 | 0.143 | |
| Migraine | 16 | 13.4 | 28 | 15.2 | 0.670 | |
| Transient global amnesia | 4 | 3.4 | 2 | 1.1 | 0.216 | |
| Cephalea | 3 | 2.5 | 6 | 3.3 | 1.000 | |
| Unstable angina | 1 | 0.8 | 6 | 3.3 | 0.252 | |
| Chronic cardiomyopathy | 0 | 0.0 | 2 | 1.1 | 0.521 | |
| Vegetations | 9 | 7.6 | 20 | 10.9 | 0.340 | |
| Pseudoinfective endocarditis | 4 | 3.4 | 8 | 4.3 | 0.770 | |
| Valve thickening and dysfunction | 5 | 4.2 | 1 | 0.5 | 0.036 | 8.03 (1.22-52.45) |
| Primary pulmonary hypertension | 1 | 0.8 | 0 | 0.0 | 0.393 | |
| Secondary pulmonary hypertension | 3 | 2.5 | 1 | 0.5 | 0.304 | |
| Major pulmonary arterial thrombosis | 2 | 1.7 | 2 | 1.1 | 0.647 | |
| Pulmonary microthrombosis | 5 | 4.2 | 16 | 8.7 | 0.133 | |
| Glomerular capillary thrombosis | 0 | 0.0 | 1 | 0.5 | 1.000 | |
| Renal artery trunk lesions | 0 | 0.0 | 2 | 1.1 | 0.521 | |
| Renal vein thrombosis | 1 | 0.8 | 0 | 0.0 | 0.393 | |
| Livedo reticularis | 26 | 21.8 | 28 | 15.2 | 0.141 | |
| Skin ulcerations | 7 | 5.9 | 11 | 6.0 | 0.973 | |
| Pseudovasculitic lesions | 12 | 10.1 | 23 | 12.5 | 0.521 | |
| Superficial cutaneous necrosis | 3 | 2.5 | 5 | 2.7 | 1.000 | |
| Amaurosis fugax | 0 | 0.0 | 2 | 1.1 | 0.521 | |
| Retinal artery thrombosis | 3 | 2.5 | 1 | 0.5 | 0.304 | |
| Optic neuropathy | 1 | 0.8 | 6 | 3.3 | 0.251 | |
| Ophthalmic sicca | 12 | 10.1 | 18 | 9.8 | 0.931 | |
| Thrombocytopenia | 32 | 26.9 | 35 | 19.0 | 0.107 | |
| Autoimmune haemolytic anemia | 14 | 11.8 | 14 | 7.6 | 0.223 | |
| Microangiopathic haemolytic anemia | 4 | 3.4 | 2 | 1.1 | 0.216 | |
| Leucopenia | 18 | 15.1 | 30 | 16.3 | 0.784 | |
| Disseminated intravascular coagulation | 2 | 1.7 | 4 | 2.2 | 1.000 | |
| C3 levels (mg/dL) | 113.0 | 92.5-138.0 | 137.0 | 109.0-167.0 | <0.001 | 23.0 (13.0-33.0) |
| C4 levels (mg/dL) | 20.6 | 14.4-28.1 | 27.8 | 18.3-37.7 | <0.001 | 6.39 (3.10-9.60) |
| Hypocomplementemia | 32 | 26.9 | 36 | 19.6 | 0.167 | |
| Platelets (x103/μL) | 216.0 | 158.8-260.0 | 234.5 | 198.0-277.0 | 0.022 | 23.0 (4.0-44.0) |
| IgG aCL positive | 68 | 57.1 | 83 | 45.4 | 0.038 | 1.64 (1.03-2.61) |
| IgM aCL positive | 62 | 52.1 | 70 | 38.0 | 0.015 | 1.78 (1.12-2.86) |
| IgG B2GP1 positive | 62 | 52.1 | 84 | 45.7 | 0.273 | |
| IgM B2GP1 positive | 62 | 52.1 | 87 | 47.3 | 0.413 | |
| LA positive | 87 | 73.1 | 133 | 72.3 | 0.875 | |
| Triple aPL positivity | 59 | 49.6 | 75 | 40.8 | 0.132 | |
| B2G-CIC positive | 35 | 29.4 | Na | Na | Na | |
| B2M-CIC positive | 98 | 82.4 | Na | Na | Na | |
| Antiplatelet agents | 77 | 64.7 | 129 | 70.1 | 0.299 | |
| Anticoagulants | 108 | 90.8 | 161 | 87.5 | 0.350 | |
| Treated | 112 | 94.1 | 170 | 92.4 | 0.519 | |
Significant p-values <0.05 are represented in bold.